Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Cited by (1,033)

Items 701–800 of 1,033

1. Protonated carbon nitride for rapid photocatalytic sterilization via synergistic oxidative damage and physical destruction.
   Xiaobiao Zhu, Chunhong Xu, Jie Mao, Yi-Zhen Zhang, Yaohui Bai · 2023 · Journal of Environmental Science
2. Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants
   Nidhi Mittal, Sahil Kumar, Raju S Rajmani, Randhir Singh, Céline Lemoine, Virginie Jakob, Sowrabha BJ, Nayana Jagannath, Madhuraj Bhat, Debajyoti Chakraborty et al. · 2023 · npj Vaccines
3. Neutralization of SARS-CoV-2 (lineage B.1.1) by hyperimmune llama (Lama glama) serum in vero cell culture
   Verónica Yaniro, Silvia Capristano, H. Bailon, Juan Lévano, M. Galarza, D. García, O. Cáceres, Carlos Padilla, Harrison Montejo, Paquita García et al. · 2023 · Revista Peruana de Medicina Experimental y Salud Pública
4. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters
   Warren R. J. de Moor, Anna‐Lise Williamson, Georgia Schäfer, Nicola Douglass, Sophette Gers, Andrew D. Sutherland, Melissa J. Blumenthal, Emmanuel Margolin, Megan L. Shaw, Wolfgang Preiser et al. · 2023 · Viruses
5. Increasing sensitivity of antibody-antigen interactions using photo-cross-linking
   A. T. Torrents de la Pena, L. M. Sewall, Rebeca de Paiva Froes Rocha, A. Jackson, P. Pratap, S. Bangaru, C. Cottrell, Subhasis Mohanty, A. Shaw, A. Ward · 2023 · Cell Reports Methods
6. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants
   H. Ishimaru, M. Nishimura, L. H. Tjan, S. Sutandhio, M. I. Marini, Gema Barlian Effendi, H. Shigematsu, Koji Kato, Natsumi Hasegawa, K. Aoki et al. · 2023 · Journal of Virology
7. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice
   Mariam Maltseva, Yannick Galipeau, Tyler Milston Renner, Lise Deschatelets, Yves Durocher, Bassel Akache, Marc‐André Langlois · 2022 · Vaccines
8. Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant
   C. Diméglio, F. Hérin, Isabelle Da-Silva, Caroline Gernigon, Marion Porcheron, S. Chapuy-Regaud, J. Izopet · 2022 · Microbiology spectrum
9. GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2
   Rena A. Mizrahi, Wendy Lin, Ashley Gras, Ariel R. Niedecken, Ellen K. Wagner, S. Keating, Nikita Ikon, Vishal A Manickam, M. Asensio, Jackson Leong et al. · 2022 · Pathogens
10. Increased body mass index linked to decreased neutralizing antibody titers of inactivated SARS‐CoV‐2 vaccine in healthcare workers
    Juan Hu, Mingcai Zhao, Yong-Mei Zhao, Wenjuan Dong, Xuemei Huang, Shao-Cheng Zhang · 2022 · Obesity Science & Practice
11. Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques
    Alexandra C. Willcox, Kevin Sung, Meghan E. Garrett, Jared Galloway, Megan A. O’Connor, Jesse H. Erasmus, Jennifer K. Logue, David W. Hawman, Helen Y. Chu, Kim J. Hasenkrug et al. · 2022 · PLoS Pathogens
12. Antigen–Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD
    Kit-Man Fung, Shu-Jung Lai, Tzu-Lu Lin, Tien‐Sheng Tseng · 2022 · Frontiers in Molecular Biosciences
13. Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants
    Divya Gupta, F. Ahmed, Dixit Tandel, Haripriya Parthasarathy, Dhiviya Vedagiri, Vishal Sah, B. Mohan, Rafiq Ahmad Khan, Chiranjeevi Kondiparthi, P. Savari et al. · 2022 · Clinical Immunology
14. Quantitative measurement of IgG to SARS‐CoV‐2 antigens using monoclonal antibody‐based enzyme‐linked immunosorbent assays
    Ingrid Sander, Sabine Kespohl, Eva Zahradnik, Philipp Göcke, Ingolf Hosbach, Burkhard Lorenz Herrmann, Thomas Brüning, Monika Raulf · 2022 · Clinical & Translational Immunology
15. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
    Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli · 2022 · Pharmacological Reviews
16. Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection
    Ye-Lin Yang, Ju Kim, Yongsu Jeong, Y. Jang · 2021 · Vaccine
17. Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay
    D. Junker, A. Dulovic, M. Becker, Teresa R. Wagner, Philipp D. Kaiser, Bjoern Traenkle, Ulrich Rothbauer, K. Kienzle, Stefanie F. Bunk, Carlotta Strümper et al. · 2021 · medRxiv
18. Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study)
    P. Jõgi, H. Soeorg, Diana Ingerainen, M. Soots, Freddy Lättekivi, P. Naaber, K. Toompere, P. Peterson, L. Haljasmägi, E. Žusinaite et al. · 2021 · Vaccine
19. Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19.
    Jie Su, Hong-Zhou Lu · 2021 · BioScience Trends
20. AI-guided discovery of the invariant host response to viral pandemics
    Debashis Sahoo, Gajanan Dattatray Katkar, Soni Khandelwal, Mahdi Behroozikhah, Amanraj Claire, Vanessa Castillo, Courtney Tindle, Mackenzie Fuller, Sahar Taheri, Thomas F. Rogers et al. · 2021 · EBioMedicine
21. XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 Spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants
    B. Vanhove, S. Marot, Ray T. Y. So, B. Gaborit, G. Evanno, I. Malet, Guillaume Lafrogne, Edwige Mevel, C. Ciron, Pierre-Joseph Royer et al. · 2021 · bioRxiv
22. Analysis of SARS-CoV-2 Mutations Over Time Reveals Increasing Prevalence of Variants in the Spike Protein and RNA-Dependent RNA Polymerase
    William M. Showers, Sonia M. Leach, K. Kechris, M. Strong · 2021 · bioRxiv
23. Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31
    Francesca Levi‐Schaffer, Ario de Marco · 2021 · British Journal of Pharmacology
24. The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced Immunity
    Emily Shang, P. Axelsen · 2020 · bioRxiv
25. Rapid and lasting generation of B-cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 disease and convalescence
    G. E. Hartley, E. Edwards, P. Aui, Nirupama Varese, S. Stojanovic, J. McMahon, A. Peleg, I. Boo, H. Drummer, P. M. Hogarth et al. · 2020 · medRxiv
26. A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform
    Ying-Ying Jiang, M. Sanyal, Noor A. Hussein, Ani Baghdasaryan, Mengzhen Zhang, Fei-Fei Wang, Fuqiang Ren, Jiachen Li, Guan-Zhou Zhu, Yifan Meng et al. · 2025 · Science Advances
27. A cGAMP‐Containing Hydrogel for Prolonged SARS‐CoV‐2 Receptor‐Binding Domain Subunit Vaccine Exposure Induces a Broad and Potent Humoral Response
    V. Böhnert, Emily C. Gale, Lauren J. Lahey, Jerry Yan, Abigail E. Powell, Ben S. Ou, J. Carozza, Ling-Yin Li, Eric A. Appel · 2024 · Advanced NanoBiomed Research
28. COVID-19 vaccine side effects and long-term neutralizing antibody response
    E. Dutcher, Elissa S. Epel, Ashley E. Mason, F. Hecht, James E. Robinson, Stacy S. Drury, A. Prather · 2024 · Annals of Internal Medicine
29. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against infection with Beta or Delta variants
    Yoshikazu Honda-Okubo, R. Bowen, Mckinzee Barker, Helle Bielefeldt-Ohmann, N. Petrovsky · 2023 · Vaccine
30. Recombinant rotavirus expressing the glycosylated S1 protein of SARS-CoV-2
    Asha A. Philip, San-Mei Hu, Jin Dai, J. Patton · 2023 · bioRxiv
31. Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity
    Alona Kuzmina, Dina Korovin, Ido Cohen-Lass, Nofar Atari, Aner Ottolenghi, Pan Hu, Michal Mandelboim, Benyamin Rosental, Elli Rosenberg, Felipe Diaz‐Griffero et al. · 2023 · Heliyon
32. Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics
    Matteo Broketa, A. Sokal, M. Mor, Pablo Canales-Herrerias, A. Perima, A. Meola, Ignacio Fernández, B. Iannascoli, Guilhem Chenon, Alexis Vandenberghe et al. · 2023 · JCI Insight
33. Pre-clinical models to define correlates of protection for SARS-CoV-2
    Caolann Brady, Tom Tipton, Stéphanie Longet, Miles W. Carroll · 2023 · Frontiers in Immunology
34. CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults
    A. Alhajjat, Catherine R. Redden, M. Langereis, Steven T. Papastefan, J. Ito, K. Ott, L. Turner, Hee-Kap Kang, Aimen F. Shaaban · 2022 · Immunobiology
35. Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern
    Hadas Cohen‐Dvashi, Jonathan J. Weinstein, Michael Katz, Maayan Eilon-Ashkenazy, Yuval Mor, Amir Shimon, Hagit Achdout, Hadas Tamir, Tomer Israely, Romano Strobelt et al. · 2022 · iScience
36. Leveraging South African HIV research to define SARS‐CoV ‐2 immunity triggered by sequential variants of concern
    Jinal N. Bhiman, Penny L. Moore · 2022 · Immunological Reviews
37. Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants
    Eric Ji Da Wang, Arup K. Chakraborty · 2022 · PLoS Computational Biology
38. Clonal Wars: Monoclonal Antibodies Against Infectious Pathogens
    Joshua Tan · 2021 · DNA and Cell Biology
39. Stabilization of the SARS-CoV-2 Receptor Binding Domain by Protein Core Redesign and Deep Mutational Scanning
    Alison C. Leonard, J. Weinstein, Paul J. Steiner, A. Erbse, S. Fleishman, T. Whitehead · 2021 · bioRxiv
40. Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor
    Wantanee Treewattanawong, Thassanai Sitthiyotha, Surasak Chunsrivirot · 2021 · Scientific Reports
41. Contributions of single-particle cryoelectron microscopy toward fighting COVID-19
    Micah Rapp, Lawrence S. Shapiro, Joachim Frank · 2021 · Trends in Biochemical Sciences
42. Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain.
    Jessie Low-Gan, Rui-Qi Huang, A. Kelley, G. W. Jenkins, D. Mcgregor, Vaughn V. Smider · 2021 · Biochemical Journal
43. Next-generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire
    R. Melani, B. D. Des Soye, Jared O. Kafader, E. Forte, M. Hollas, Voislav Blagojevic, F. Negrão, J. McGee, Bryon S. Drown, Cameron Lloyd-Jones et al. · 2021 · medRxiv
44. Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma
    Pavlo Gilchuk, Isaac P. Thomsen, Sandra M. Yoder, Eric J. Brady, James D. Chappell, Laura J. Stevens, Mark R. Denison, Rachel E. Sutton, Rita E. Chen, Laura A. VanBlargan et al. · 2021 · iScience
45. Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
    L. Jia, Yan-Ping Liu, L. Tian, Chao Xiong, Xin Xu, Honge Qu, Wei-Xi Xiong, Dong Zhou, Feng Wang, Zheng Liu et al. · 2021 · MedComm
46. Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells
    C. Riou, Georgia Schäfer, E. du Bruyn, R. Goliath, C. Stek, H. Mou, D. Hung, K. Wilkinson, R. Wilkinson · 2021 · European Respiratory Journal
47. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines
    Jian-Hua Li, Ping Wang, K. Tracey, Haichao Wang · 2021 · Molecular Medicine
48. Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks
    Emily N. Gallichotte, Mary Nehring, Michael C. Young, Sierra Pugh, Nicole R. Sexton, Emily A. Fitzmeyer, Kendra M. Quicke, Megan Richardson, Kristy L. Pabilonia, Nicole P. Ehrhart et al. · 2021 · Microbiology Spectrum
49. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
    D. Focosi, F. Maggi, M. Franchini, A. Aguzzi, M. Lanza, A. Mazzoni, F. Menichetti · 2021 · Clinical Microbiology and Infection
50. Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic
    Monty A Montano · 2021 · AIDS Research and Human Retroviruses
51. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge
    Xiangchuan He, Longfei Ding, Kangli Cao, Hao-Ran Peng, C. Gu, Yu-Tang Li, Duo-Duo Li, Lanlan Dong, Xiujing Hong, Xiangwei Wang et al. · 2021 · Emerging Microbes and Infections
52. Dosing Considerations for Antibodies Against COVID-19
    Million A. Tegenge, I. Mahmood, E. Struble, B. Golding · 2020 · Drugs in R&D
53. Interferon-mediated NK cell activation increases cytolytic activity against T follicular helper cells and limits antibody response to SARS-CoV-2
    Izumi de los Rios Kobara, Radeesha D. Jayewickreme, Madeline J. Lee, Aaron J. Wilk, Andra L. Blomkalns, Kari C. Nadeau, Samuel Yang, A. Rogers, C. Blish · 2025 · Nature Immunology
54. High-throughput synthesis and specificity characterization of natively paired influenza hemagglutinin antibodies with oPool+ display
    Wenhao O. Ouyang, Hui-Bin Lv, Wen-Kan Liu, Rui-Peng Lei, Z. Mou, T. Pholcharee, L. Talmage, Mei-Xuan Tong, Wei Ji, Yi-Quan Wang et al. · 2025 · Science Translational Medicine
55. A systems biology approach to define SARS-CoV-2 correlates of protection
    Caolann Brady, Tom Tipton, Oliver T. Carnell, Stéphanie Longet, Karen E. Gooch, Yper Hall, Javier Salguero, Adriana Tomić, Miles W. Carroll · 2025 · npj Vaccines
56. A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site
    Siqi He, Jiali Wang, Hanyi Chen, Zhaohui Qian, Keping Hu, Bingjie Shi, Jianxun Wang · 2023 · Vaccines
57. Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
    Zrinka Sertić, M. Lucijanić, S. Bašić-Kinda, Ranka Serventi Seiwerth, V. Periša, D. Sertić, B. Coha, D. Pulanić, Z. Perić, L. Desnica et al. · 2022 · Biomedicines
58. A novel plasma proteomic‐based model for predicting liver fibrosis in HIV/HBV co‐infected adults
    Rui Yuan, Yong-Xi Zhang, Li-Ping Deng, Xing-Xia Yu, K. Zhuang, Xiao-Ping Chen, Q. Cao, H. Ping, Heng-Ning Ke, X. Gui et al. · 2022 · Journal of Medical Virology
59. A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters
    S. Chaturvedi, N. Beutler, M. Pablo, Gustavo Vasen, Xinyue Chen, Giuliana P. Calia, Lauren Buie, R. Rodick, Davey M. Smith, T. Rogers et al. · 2022 · bioRxiv
60. Physical-Chemical Regulation of Membrane Receptors Dynamics in Viral Invasion and Immune Defense
    Rui Qin, Chen-Yi An, Wei Chen · 2022 · Journal of Molecular Biology
61. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID‐19 cohorts by chemiluminescent immunoassays
    X. Dou, E. Wang, Ruiwei Jiang, Min Li, D. Xiong, Bao-Qing Sun, Xiu-Ming Zhang · 2022 · Immunity, Inflammation and Disease
62. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants
    Mikako Ueno, Naoko Iwata‐Yoshikawa, Akihiro Matsunaga, Tadashi Okamura, Sho Saito, Shinobu Ashida, Isao Yoshida, Mami Nagashima, Hiroyuki Asakura, Yu Yaoita et al. · 2022 · Antiviral Research
63. BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
    Anna Kaznadzey, Maria N. Tutukina, Tatiana A. Bessonova, Maria L. Kireeva, Ilya A. Mazo · 2022 · Frontiers in Immunology
64. Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2
    Reginald M. Gorczynski, Robyn Alice Lindley, Edward J. Steele, Nalin Chandra Wickramasinghe · 2021 · Journal of Personalized Medicine
65. Longitudinal Dynamics of Human B-Cell Response at the Single-Cell Level in Response to Tdap Vaccination
    Indu Khatri, A. M. Diks, E. van den Akker, L. Oosten, J. Zwaginga, M. Reinders, J. V. van Dongen, M. Berkowska · 2021 · bioRxiv
66. Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients
    Olivier Bylicki, D. Delarbre, A. Mayet, Audrey Ferrier, Anne Perisse, Carine Malle, J. Cobola, A. Bronstein, Nastasia Menoud, Elodie Valero-Biance et al. · 2021 · International Journal of Infectious Diseases
67. A rapid assay for SARS-CoV-2 neutralizing antibodies that is insensitive to antiretroviral drugs
    De-Li Huang, J. Tran, Linghang Peng, Lin-Lin Yang, Raymond T. Suhandynata, M. Hoffman, Fang-Zhu Zhao, G. Song, Wan-ting He, Oliver Limbo et al. · 2021 · Journal of Immunology
68. Homologous and heterologous serological response to the N‐terminal domain of SARS‐CoV‐2 in humans and mice
    Huibin Lv, O. Tsang, Ray T. Y. So, Yi-Quan Wang, M. Yuan, Hejun Liu, Garrick K. Yip, Q. Teo, Yihan Lin, Wei-Wen Liang et al. · 2021 · European Journal of Immunology
69. Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses
    G. Chuang, Chen-Hsiang Shen, C. S. Cheung, J. Gorman, A. Creanga, M. Joyce, K. Leung, Reda Rawi, Ling-Shu Wang, E. Yang et al. · 2021 · Frontiers in Immunology
70. Epitope profiling of coronavirus-binding antibodies using computational structural modelling
    Sarah A. Robinson, M. Raybould, Constantin Schneider, Wing K. Wong, Claire Marks, Charlotte M. Deane · 2021 · bioRxiv
71. Passive Immunity Should and Will Work for COVID-19 for Some Patients
    Nevio Cimolai · 2021 · Clinical Hematology International
72. Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction
    X. Qiang, Shu Zhu, Jian-Hua Li, Weiqiang Chen, Huan Yang, Ping Wang, K. Tracey, Haichao Wang · 2021 · Journal of Leukocyte Biology
73. Distinct systemic and mucosal immune responses to SARS-CoV-2
    Nikaïa Smith, P. Gonçalves, B. Charbit, L. Grzelak, Maxime Beretta, C. Planchais, T. Bruel, V. Rouilly, V. Bondet, J. Hadjadj et al. · 2021 · medRxiv
74. In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses
    Andrea Castro, Kivilcim Ozturk, M. Zanetti, H. Carter · 2021 · PLoS ONE
75. Pharmacotherapeutics of SARS-CoV-2 Infections
    Bhavesh D. Kevadiya, Jatin Machhi, J. Herskovitz, Maxim D. Oleynikov, Wilson R. Blomberg, N. Bajwa, Dhruvkumar Soni, Srijanee Das, M. Hasan, Milankumar Patel et al. · 2021 · Journal of Neuroimmune Pharmacology
76. Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance
    Yuichiro Yamamoto, Kohji Noguchi · 2025 · Biomolecules
77. Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens
    Masanori Isogawa, Taishi Onodera, Akira Ainai, Ryutaro Kotaki, Takayuki Kanno, Shinji Saito, Minoru Tobiume, Kenzo Tokunaga, Megumi Hara, Yoshio Hirota et al. · 2025 · Scientific Reports
78. A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein
    S. Schendel, Xiao-Ying Yu, P. Halfmann, J. Mahita, Brendan Ha, K. Hastie, Hao-Yang Li, D. Bedinger, Camille B. Troup, Kan Li et al. · 2025 · Cell Reports
79. The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2
    Manish K. Dhawan, Nanamika Thakur, Manish Kumar Sharma, Ali Ahmed Rabaan · 2025 · Biomedicine & Pharmacotherapy
80. Lentinan Reduces Transmission Efficiency of COVID-19 by Changing Aerodynamic Characteristic of Exhaled SARS-CoV-2 Aerosols in Golden Hamsters
    Cheng Zhang, Jiaming Li, Huan Cui, Yi-Fei Jin, Zhaoliang Chen, Lei Zhang, Sihui Song, Bing Lu, Zhong-Yi Wang, Zhen-Dong Guo · 2025 · Microorganisms
81. A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses
    S. Thimmiraju, R. Adhikari, JeAnna R. Redd, M. J. Villar, Jungsoon Lee, Zhu-Yun Liu, Yi-Lin Chen, Suman Sharma, Amandeep Kaur, Nestor L. Uzcategui et al. · 2024 · npj Vaccines
82. The characteristics of BCR‐CDR3 repertoire in COVID‐19 patients and SARS‐CoV‐2 vaccinated volunteers
    Jiaping Xiao, Yan Luo, Yangyang Li, Xin-Sheng Yao · 2024 · Journal of Medical Virology
83. Identification of B cell subsets based on antigen receptor sequences using deep learning
    Hyunho Lee, Kyoungseob Shin, Yongju Lee, Soobin Lee, Seungyoun Lee, Eunjae Lee, S. Kim, H. Shin, Jong Hoon Kim, Jun-Ho Chung et al. · 2024 · bioRxiv
84. A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
    Zhe Lv, Song-Qin Lv, Qin Li, Yafei Xia, Zai-Neng Feng, Haohong Zhang, Haihao Yang, Zhao Wu, Nanting Zou, Qing-Yan Mo et al. · 2023 · Frontiers in Immunology
85. Metabolic Profiling, Antiviral Activity and the Microbiome of Some Mauritian Soft Corals
    Deeya Jahajeeah, M. Ranghoo-Sanmukhiya, Georgia Schäfer · 2023 · Marine Drugs
86. Comparative Study of the Mutations Observed in the SARS-CoV-2 RBD Variants of Concern and Their Impact on the Interaction with the ACE2 Protein
    M. Ghoula, Audrey Deyawe Kongmeneck, Rita Eid, A. Camproux, G. Moroy · 2023 · Journal of Physical Chemistry B
87. Natural infection versus hybrid (natural and vaccination) humoral immune response to SARS-CoV-2: a comparative paired analysis
    Laila AbdelWareth, Farida Alhousani, R. Abuyadek, J. Donnelly, Andrea Leinberger-Jabari, S. Atef, Rami H. Al-Rifai · 2023 · Frontiers in Immunology
88. The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
    W. Tolbert, Yao-Zong Chen, Lu-Lu Sun, M. Benlarbi, Shi-Lei Ding, Rohini Manickam, Emily Pangaro, Dung N. Nguyen, Suneetha Gottumukkala, M. Côté et al. · 2023 · Frontiers in Immunology
89. Severe COVID-19: Drugs and Clinical Trials
    Hazael Ramiro Ceja-Gálvez, Francisco Israel Renteria-Flores, Ferdinando Nicoletti, Jorge Hernández‐Bello, Gabriela Macedo Ojeda, José Francisco Muñóz-Valle · 2023 · Journal of Clinical Medicine
90. RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers
    R. Aguilar, Xue Li, C. Crowell, Teresa K. Burrell, M. Vidal, R. Rubio, A. Jiménez, P. Hernández-Luis, D. Hofmann, H. Mijočević et al. · 2023 · Microbiology spectrum
91. How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?
    Stéphanie Pons, Fabrice Uhel, Eric Frapy, Youssouf Sérémé, Lara Zafrani, Hugues Aschard, David Skurnik · 2022 · Stem Cell Reviews and Reports
92. Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants
    Justin Mark Lunderberg, Sanjucta Dutta, Ai-ris Yonekura Collier, Jeng-Shin Lee, Yen‐Ming Hsu, Qiao Wang, Weina Zheng, Shushun Hao, Haohai Zhang, Lili Feng et al. · 2022 · Frontiers in Immunology
93. SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients
    A. Celikgil, A. Massimi, A. Nakouzi, Natalia G. Herrera, Nicholas C. Morano, James H. Lee, H. Yoon, S. Garforth, S. Almo · 2022 · bioRxiv
94. Broad tricyclic ring inhibitors block SARS-CoV-2 spike function required for viral entry
    Sneha Ratnapriya, Anthony R Braun, Héctor Cervera Benet, D. Carlson, Shi-Lei Ding, C. Paulson, Neeraj Mishra, J. Sachs, C. Aldrich, A. Finzi et al. · 2022 · ACS Infectious Diseases
95. Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines
    Si-Ling Wang, Ding-Hui Wu, Hua-long Xiong, Juan Wang, Zimin Tang, Zi-Hao Chen, Yi-Zhe Wang, Ya-Li Zhang, Dong Ying, Xue Lin et al. · 2022 · Frontiers in Immunology
96. Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
    Xiaohui Wei, Na Rong, Jiangning Liu · 2022 · Frontiers in Immunology
97. Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease
    Ajit Monteiro, Arthur J Chang, R. Welliver, S. Baron, M. Hicar · 2022 · Virology
98. Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
    Gonzalo Almanza, Alex E. Clark, Valentina L. Kouznetsova, Eduardo Olmedillas, Andrea Castro, Igor F. Tsigelny, Yan Wu, George F. Gao, Sandra Lawrynowicz Leibel, William A. Bray et al. · 2022 · PLoS Pathogens
99. Point mutations in SARS-CoV-2 variants induce long-range dynamical perturbations in neutralizing antibodies
    Dhiman Ray, Riley Quijano, I. Andricioaei · 2022 · Chemical Science
100. SARS-CoV-2 Spike evolution influences GBP and IFITM sensitivity
     Dejan Mesner, Ann-Kathrin Reuschl, M. Whelan, Taylor Bronzovich, Tafhima Haider, Lucy G. Thorne, G. Towers, Clare Jolly · 2022 · bioRxiv